



EAACI 2026

12-15 JUNE
ISTANBUL
TÜRKIYE

**Vision Zero: A Future Free from
Allergy and Asthma Burden**



www.eaaci.org

#EAACICongress2026





Abstract Prize Winners

Oral abstract sessions (OAS)

&

Oral Abstracts sessions
on Clinical Trials (OAS-CT)



Presenter	Session Name	Session Reference	Abstract Title	Abstract Id
Alqurashi Waleed	Predicting anaphylaxis: risk, severity and cofactors	OAS01	Pediatric Risk Evaluation for Predicting Anaphylaxis Recurrence in Emergency Department (PREPARED) Score: Derivation and Validation	000339
Demoly Pascal	Expanding the scope of AIT	OAS02	Reduced risk of respiratory infections with liquid sublingual immunotherapy in patients with allergic rhinitis with or without asthma in the real-world EfficAPSI study	000511
Yildirim Abdullah	Real world results of biologics in asthma	OAS03	From Response to Clinical Remission with Biologic Therapy: Single-Center Real-World Data in Severe Asthma	000466
Laguna Martinez Jose Julio	Adult drug allergy	OAS04	Reducing diagnostic uncertainty after perioperative hypersensitivity: organisational factors identified by national allergy and anaesthesiology surveys in Spain	000787
Chang Chia-Lun	The prevention and prediction of food allergy	OAS05	Early life skin lysophosphatidylcholine may predict the development of food allergy in infants over and above a published risk prediction model	000474
Leffler Jonatan	Cellular mechanisms of immune regulation	OAS06	Functional evaluation of rare plasmacytoid dendritic cells in children with asthma	000471
Meric Zeynep	Two faces of immune imbalance: immunodeficiencies and allergic diseases	OAS07	Clinical and Immunological Spectrum of Spondyloenchondrodysplasia: Insights from Type I Interferon Signatures	000156
Kaymakoğlu Gülçin	Markers of sensitization and tolerance in food allergy	OAS08	The Importance of Clinical and Laboratory Findings in Predicting Tolerance Development in Food Protein-Induced Enterocolitis Syndrome	001074
Firinu Davide	Angioedema	OAS09	POLYPHEMOS study: a cartography of normal C1-INH-HAE and recurrent isolated angioedema among the Italian Reference Centers Network for Angioedema (ITACA) over the last 10 years	000840
Lopez Juan-Felipe	Immunologic mechanisms and biomarkers in AIT	OAS10	Insights on the Unknown Role of IgD ⁺ Memory B Cells in Allergy and Tolerance	001381



Presenter	Session Name	Session Reference	Abstract Title	Abstract Id
Anshory Muhammad	Microbiome profile in controlling inflammation	OAS11	Cutaneous Microbiome Profiles in Individuals With HIV: Links to Antiretroviral Treatment and Host Characteristics	001953
Yao Shengyang	Advancing AIT clinical efficacy and novel combination	OAS12	Risk Stratification for Systemic Reactions During House Dust Mite Subcutaneous Immunotherapy: A Multicenter Real-World Prediction Model	001402
Kim Wanjin	Atopic dermatitis urticaria	OAS13	Skin Microbiome Dysbiosis and Immune Activation in Dupilumab Associated Head and Neck Dermatitis: A Shotgun Metagenomic Analysis	000721
Gemici Karaaslan Hatice Betul	Pediatric drug allergy	OAS14	The Implementation of Monocyte-Derived Dendritic Cell-Based Lymphocyte Transformation Testing in Pediatric SCAR Patients	001775
Gilles Stefanie	Climate and Aeroallergens: where are we going?	OAS15	Exposure of nasal epithelial cells with pollen aerosols and coronaviruses in a near-physiological in vitro model	100340
Ryser Fabio	Inflammation in the nose	OAS17	Improvement of Mixed Inflammatory Environment in Nasal Secretions of Diffuse Type 2 CRSwNP under Dupilumab	001776
Niegowska Malgorzata	Food allergy treatments: not just oral immunotherapy	OAS18	Long-term effectiveness and safety of paediatric cow's milk oral immunotherapy in real life: outcomes with and without omalizumab support	000911
Gu Wenjing	Childhood asthma under the lens	OAS19	Aberrant Airway Fucosylation Impairs Epithelial Barrier Integrity and Drives Asthma Pathogenesis	000290
Tadik Ferhat	Molecular Allergology applied in clinics	OAS20	Comparison of Molecular Tests and Skin Tests in Patients With Food Allergy and/or Polysensitization	001045
Jesus João	Clinical biomarkers in pediatric and adult onset asthma	OAS21	Body composition and airway inflammation in children: sex-specific associations between lean and muscle mass with FeNO	001797



Presenter	Session Name	Session Reference	Abstract Title	Abstract Id
Reitsma Sietze	Transforming disease course: clinical outcomes and remission with biologics	OAS23	Clinically meaningful improvements in upper airway outcomes with dupilumab vs omalizumab by prior surgery status in severe chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST study)	001393
D'alesio Paola	From risk to resilience: prevention of allergic diseases in childhood	OAS24	Therapeutic Efficacy of Cutaneous Application of Postbiotic N-(1-carbamoyl-2-phenyl-ethyl) Butyramide (FBA) in Pediatric Patients Affected by Atopic Dermatitis: The BuPAD Trial	002056
Zeyneloglu Can	Epithelial barrier and systemic inflammation: from nose to gut	OAS25	Food emulsifier Polysorbate 80 Drives Gut Barrier Dysfunction and Systemic Inflammation Through Oxidative Stress	001618
Gerasymchuk Dmytro	It's pollen time!	OAS26	Prevalence of Sensitization to Ambrosia Pollen among Ukrainian Military Personnel on the Front Line (2022–2025)	001946
Bärhold Friederike	From biologics to cold steel	OAS27	Evaluation of simultaneous dual biological therapy in CRSwNP and concomitant type 2 diseases	000607
López-Rodríguez Juan	From mechanisms to meaningful outcomes: Biologics in respiratory disease	OAS28	Dupilumab + AIT: CD8 ⁺ T Cells Uncover a Potent Immune Reset in Severe Allergic patients	000142
Carucci Laura	Pediatric food allergy: from diet to disease modulation	OAS29	Formula Choice Shapes Epigenetic, Immunological and Gut Microbiota trajectories toward Immune Tolerance in Children with IgE-Mediated Cow's Milk Allergy: Mechanistic Insights from the EPICMA Study	001338
Loutrari Heleni	Asthma	L-OAS01	Comprehensive multi-omics profiling reveals airway microbiome dynamics and immune restoration patterns under mepolizumab treatment in patients with nasal polyps and comorbid asthma	100240
Sculco Eleonora	Immune deficiencies and autoimmunity	L-OAS02	Toward Safer Imaging in COVID: Preliminary Results of Low-Dose Chest CT with Visual and Automated Evaluation	100280
Metz Martin	Skin Allergy	L-OAS03	Remibrutinib demonstrated superior efficacy vs placebo and favorable safety in patients with chronic inducible urticaria in the phase 3 REMIND study	100213



Presenter	Session Name	Session Reference	Abstract Title	Abstract Id
Antunes Diogo	Drug allergy	L-OAS04	Risk stratification scores for suspected beta-lactam allergy: Comparative performance of PEN-FAST and BL-Predictor	100525
Boyd Holly	Allergy diagnosis	L-OAS05	The Basophil Activation Test (BAT) identifies high-risk cow's milk allergic children: clinically actionable severity cut-offs and low-dose reactivity	100149
Brettig Tim	Allergen immunotherapy	L-OAS06	OFC before OIT: Accurate diagnosis of peanut allergy using a threshold oral food challenge in the ADAPT peanut oral immunotherapy program	100480
zhou Yu Wei	ENT	L-OAS07	Tas2Rs activation suppresses recurrent allergic rhinitis via a Tuft cell-CCL3 axis	100064
MUCHEMBLED Lila	Anaphylaxis	L-OAS09	Paediatric perioperative hypersensitivity reactions in France: Analysis of the GERAP network database	100167
Cancian Mauro	Clinical trials on allergic diseases	OAS-CT1	Oral Deucricbant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: End of Progression Results in the Phase 3 RAPIDe-3 Trial	000028

